Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF20A | O95235 | 11/20 | 0.79 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 4/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274837 | 1.00 | KIF20A (0.79) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL19193585 | 0.90 | KIF20A (0.78) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2727490 | 0.88 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2727783 | 0.88 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2727786 | 0.88 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2727484 | 0.88 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL19192415 | 0.86 | KIF20A (0.75) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2725529 | 0.85 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2725053 | 0.85 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A | |
| SCHEMBL2725057 | 0.85 | KIF20A (1.00) | KIF20ADYRK1ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | claimed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | claimed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | claimed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | claimed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1692136-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | KIF20A 3861/4885DYRK1A 1064/4885NPC1 1969/4885 |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF20A 871/4885DYRK1A 597/4885NPC1 2848/4885 |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF20A 871/4885DYRK1A 597/4885NPC1 2848/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | KIF20A 4204/4885DYRK1A 3109/4885NPC1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.